302P A multicenter, open-label, dose-escalation (DE), first-in-human study of VEGFRs and CSF1R inhibitor SYHA1813 in patients (pts) with recurrent high-grade gliomas (HGG) or advanced solid tumors

W Li,Y Mao,Y Lin,T Lei,H Wang,J Qiu,Y Li,Z Kang,Y Yang,S Li,J Zhang,Y Su

doi:10.1016/j.annonc.2022.07.436

302P A multicenter, open-label, dose-escalation (DE), first-in-human study of VEGFRs and CSF1R inhibitor SYHA1813 in patients (pts) with recurrent high-grade gliomas (HGG) or advanced solid tumors

W Li, Y Mao + Show 10 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.436

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

#Colony-stimulating Factor 1 Receptor #Vascular Endothelial Growth Factor Receptors + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

SYHA1813 is a novel small-molecule vascular endothelial growth factor receptors (VEGFRs)/ colony-stimulating factor 1 receptor (CSF1R) inhibitor, exerting synergistic antitumor effects through inhibiting angiogenesis and modulating macrophage polarity in preclinical models. We report preliminary results from a phase Ⅰ, DE study of SYHA1813 in pts with recurrent or advanced solid tumors including HGG.

Full Text